EP1024810A4 - METHOD FOR OPTIMIZING RETINAL AND THE HEALTH OF THE OPTICAL NERVE - Google Patents

METHOD FOR OPTIMIZING RETINAL AND THE HEALTH OF THE OPTICAL NERVE

Info

Publication number
EP1024810A4
EP1024810A4 EP98931510A EP98931510A EP1024810A4 EP 1024810 A4 EP1024810 A4 EP 1024810A4 EP 98931510 A EP98931510 A EP 98931510A EP 98931510 A EP98931510 A EP 98931510A EP 1024810 A4 EP1024810 A4 EP 1024810A4
Authority
EP
European Patent Office
Prior art keywords
optic nerve
nerve health
retinal
optimizing
optimizing retinal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98931510A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1024810A1 (en
Inventor
Michael S Sugrue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9800449.2A external-priority patent/GB9800449D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP1024810A1 publication Critical patent/EP1024810A1/en
Publication of EP1024810A4 publication Critical patent/EP1024810A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP98931510A 1997-06-26 1998-06-22 METHOD FOR OPTIMIZING RETINAL AND THE HEALTH OF THE OPTICAL NERVE Withdrawn EP1024810A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US50835 1987-05-13
US5083597P 1997-06-26 1997-06-26
GB9800449 1998-01-09
GBGB9800449.2A GB9800449D0 (en) 1998-01-09 1998-01-09 Method for optimizing retinal and optic nerve health
PCT/US1998/013038 WO1999000133A1 (en) 1997-06-26 1998-06-22 Method for optimizing retinal and optic nerve health

Publications (2)

Publication Number Publication Date
EP1024810A1 EP1024810A1 (en) 2000-08-09
EP1024810A4 true EP1024810A4 (en) 2003-06-11

Family

ID=26312917

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98931510A Withdrawn EP1024810A4 (en) 1997-06-26 1998-06-22 METHOD FOR OPTIMIZING RETINAL AND THE HEALTH OF THE OPTICAL NERVE

Country Status (5)

Country Link
EP (1) EP1024810A4 (ja)
JP (1) JP2002506461A (ja)
AU (1) AU740874B2 (ja)
CA (1) CA2294343A1 (ja)
WO (1) WO1999000133A1 (ja)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948801A (en) * 1998-03-09 1999-09-07 Alcon Laboratories, Inc. Treatment of retinal edema with brinzolamide
US6174524B1 (en) 1999-03-26 2001-01-16 Alcon Laboratories, Inc. Gelling ophthalmic compositions containing xanthan gum
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
ES2199873T3 (es) 1999-11-01 2004-03-01 Alcon Inc. Composiciones farmaceuticas que contienen un farmaco antibiotico de fluoroquinolona y goma xantan.
PL199321B1 (pl) 2000-07-28 2008-09-30 Alcon Inc Kompozycje farmaceutyczne zawierające tobramycynę i gumę ksantanową
US7109208B2 (en) 2001-04-11 2006-09-19 Senju Pharmaceutical Co., Ltd. Visual function disorder improving agents
JP4948176B2 (ja) 2004-09-28 2012-06-06 千寿製薬株式会社 キサンタンガムおよびアミノ酸を含有する眼科用組成物
PL1911447T3 (pl) 2005-07-11 2010-03-31 Senju Pharma Co Preparat kropli do oczu zawierający gumę ksantanową i terpenoid
US7875271B2 (en) 2006-03-23 2011-01-25 Senju Pharmaceutical Co., Ltd. Ophthalmic composition comprising xanthan gum and glucose
US20100063035A1 (en) 2006-12-15 2010-03-11 Nicox S.A. Carbonic anhydrase inhibitors derivatives
US8222156B2 (en) 2006-12-29 2012-07-17 Lam Research Corporation Method and apparatus for processing a substrate using plasma
JP5305710B2 (ja) * 2008-03-31 2013-10-02 株式会社ニデック ドルゾラミド塩酸塩点眼液

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0033042A1 (en) * 1980-01-28 1981-08-05 Merck & Co. Inc. Ophthalmic inserts for lowering intraocular pressure comprising carbonic anhydrase inhibitors
EP0036351A2 (en) * 1980-03-04 1981-09-23 Merck & Co. Inc. Ophthalmic compositions of carbonic anhydrase inhibitors for topical application in the treatment of elevated intraocular pressure
EP0507224A2 (en) * 1991-03-27 1992-10-07 Alcon Laboratories, Inc. Use of combinations of gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
WO1993016701A2 (en) * 1992-02-21 1993-09-02 Alcon Laboratories, Inc. Topical antiglaucoma compositions comprising carbonic anhydrase inhibitors and beta-blockers
EP0590786A1 (en) * 1992-08-28 1994-04-06 Alcon Laboratories, Inc. Use of certain anionic surfactants to enhance antimicrobial effectiveness of opthalmic compositions
WO1996037203A1 (en) * 1995-05-22 1996-11-28 Advanced Research & Technology Institute Method to increase retinal blood flow

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378703A (en) * 1990-04-09 1995-01-03 Alcon Laboratories, Inc. Sulfonamides useful as carbonic anhydrase inhibitors

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0033042A1 (en) * 1980-01-28 1981-08-05 Merck & Co. Inc. Ophthalmic inserts for lowering intraocular pressure comprising carbonic anhydrase inhibitors
EP0036351A2 (en) * 1980-03-04 1981-09-23 Merck & Co. Inc. Ophthalmic compositions of carbonic anhydrase inhibitors for topical application in the treatment of elevated intraocular pressure
EP0507224A2 (en) * 1991-03-27 1992-10-07 Alcon Laboratories, Inc. Use of combinations of gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
WO1993016701A2 (en) * 1992-02-21 1993-09-02 Alcon Laboratories, Inc. Topical antiglaucoma compositions comprising carbonic anhydrase inhibitors and beta-blockers
EP0590786A1 (en) * 1992-08-28 1994-04-06 Alcon Laboratories, Inc. Use of certain anionic surfactants to enhance antimicrobial effectiveness of opthalmic compositions
WO1996037203A1 (en) * 1995-05-22 1996-11-28 Advanced Research & Technology Institute Method to increase retinal blood flow

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHIOU G C Y ET AL: "EFFECTS OF ANTIGLAUCOMA DRUGS ON OCULAR BLOOD FLOW IN OCULAR HYPERTENSIVE RABBITS", JOURNAL OF OCULAR PHARMACOLOGY, MARY ANN LIEBERT, INC. NEW YORK, NY, US, vol. 9, no. 1, 21 March 1993 (1993-03-21), pages 13 - 24, XP000993431, ISSN: 8756-3320 *
RASSAM S M B ET AL: "THE EFFECT OF ACETAZOLAMIDE ON THE RETINAL CIRCULATION", EYE, ROYAL COLLEGE OF OPHTALMOLOGISTS, LONDON, GB, vol. 7, no. PART 5, 1993, pages 697 - 702, XP002059279 *
See also references of WO9900133A1 *

Also Published As

Publication number Publication date
AU740874B2 (en) 2001-11-15
EP1024810A1 (en) 2000-08-09
WO1999000133A1 (en) 1999-01-07
JP2002506461A (ja) 2002-02-26
CA2294343A1 (en) 1999-01-07
AU8162298A (en) 1999-01-19

Similar Documents

Publication Publication Date Title
IL134868A0 (en) A method for maintaining or improving skin health
AU7383398A (en) Therapeutic glasses and method for using the same
EP0789592A4 (en) GENE EYE THERAPY
GB9503949D0 (en) Oil well treatment
IL113723A0 (en) An eye implant
IL131821A0 (en) Defibrillator apparatus and method
GB9518888D0 (en) Device and method for transcutaneous surgery
GB0015133D0 (en) Formation treatment method using deformable particles
EP1024810A4 (en) METHOD FOR OPTIMIZING RETINAL AND THE HEALTH OF THE OPTICAL NERVE
GB9410320D0 (en) Novel therapeutic method
GB9719161D0 (en) New therapeutic method
AU6242498A (en) Methods for treating central and peripheral nerve pain
AU3206195A (en) Optic nerve health
AUPP618098A0 (en) Apparatus and method for avoiding ocular muscular fatigue
GB9515868D0 (en) Therapeutic method
GB2290096B (en) Oil well treatment
GB9714841D0 (en) Treatment method
ZA982579B (en) Method of stimulating nerve regeneration
GB9800449D0 (en) Method for optimizing retinal and optic nerve health
GB9708400D0 (en) Sterilising arrangement and method
GB9507848D0 (en) Fatigue related diseases
AUPO943497A0 (en) Apparatus and method for avoiding ocular muscular fatigue
GB9719189D0 (en) New therapeutic method
GB9719176D0 (en) New therapeutic method
GB9703102D0 (en) Treatment method

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000126

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20030429

17Q First examination report despatched

Effective date: 20031106

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040317